241 related articles for article (PubMed ID: 27292023)
21. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
22. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
23. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
24. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
25. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
26. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma.
Liang J; Zhang Y; Jiang G; Liu Z; Xiang W; Chen X; Chen Z; Zhao J
Oncol Res; 2013; 21(2):83-91. PubMed ID: 24406044
[TBL] [Abstract][Full Text] [Related]
27. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
28. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
29. A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.
Brockett JS; Manalo T; Zein-Sabatto H; Lee J; Fang J; Chu P; Feng H; Patil D; Davidson P; Ogan K; Master VA; Pattaras JG; Roberts DL; Bergquist SH; Reyna MA; Petros JA; Lerit DA; Arnold RS
Genetics; 2024 Apr; 226(4):. PubMed ID: 38290049
[TBL] [Abstract][Full Text] [Related]
30. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
31. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
32. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
Simon JM; Hacker KE; Singh D; Brannon AR; Parker JS; Weiser M; Ho TH; Kuan PF; Jonasch E; Furey TS; Prins JF; Lieb JD; Rathmell WK; Davis IJ
Genome Res; 2014 Feb; 24(2):241-50. PubMed ID: 24158655
[TBL] [Abstract][Full Text] [Related]
33. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract][Full Text] [Related]
34. An actin-WHAMM interaction linking SETD2 and autophagy.
Seervai RNH; Grimm SL; Jangid RK; Tripathi DN; Coarfa C; Walker CL
Biochem Biophys Res Commun; 2021 Jun; 558():202-208. PubMed ID: 33036756
[TBL] [Abstract][Full Text] [Related]
35. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
36. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
Elife; 2014 May; 3():e02482. PubMed ID: 24843002
[TBL] [Abstract][Full Text] [Related]
37. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
[TBL] [Abstract][Full Text] [Related]
38. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Dalgliesh GL; Furge K; Greenman C; Chen L; Bignell G; Butler A; Davies H; Edkins S; Hardy C; Latimer C; Teague J; Andrews J; Barthorpe S; Beare D; Buck G; Campbell PJ; Forbes S; Jia M; Jones D; Knott H; Kok CY; Lau KW; Leroy C; Lin ML; McBride DJ; Maddison M; Maguire S; McLay K; Menzies A; Mironenko T; Mulderrig L; Mudie L; O'Meara S; Pleasance E; Rajasingham A; Shepherd R; Smith R; Stebbings L; Stephens P; Tang G; Tarpey PS; Turrell K; Dykema KJ; Khoo SK; Petillo D; Wondergem B; Anema J; Kahnoski RJ; Teh BT; Stratton MR; Futreal PA
Nature; 2010 Jan; 463(7279):360-3. PubMed ID: 20054297
[TBL] [Abstract][Full Text] [Related]
39. Histone methyltransferase Setd2 is critical for the proliferation and differentiation of myoblasts.
Yi X; Tao Y; Lin X; Dai Y; Yang T; Yue X; Jiang X; Li X; Jiang DS; Andrade KC; Chang J
Biochim Biophys Acta Mol Cell Res; 2017 Apr; 1864(4):697-707. PubMed ID: 28130125
[TBL] [Abstract][Full Text] [Related]
40. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
